Ischemic Preconditioning of Liver in Cadaver Donors

This study has been completed.
Sponsor:
Information provided by:
Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT00245830
First received: October 26, 2005
Last updated: April 27, 2007
Last verified: March 2007
  Purpose

The long-term goals of this proposal are to develop clinical protocols of donor preconditioning to improve liver graft function and ameliorate complications of poor graft function after liver transplantation. Achievement of these objectives would improve liver recipient outcomes, increase utilization of livers and alleviate the current critical shortage of livers for transplantation. More stringent liver donor selection intended to decrease the complications of poor graft function conflicts directly with efforts to maximize the use of donor livers. Ischemic preconditioning (IPC) of liver attenuates hepatic ischemia reperfusion injury (IRI) in animals. Preliminary data show hepatic IPC effectively decreases IRI following hepatic resection in humans.

The specific aims of this project are: AIM 1: To test the hypothesis that 10 minutes of hepatic ischemic preconditioning in deceased donors would improve liver graft function and decrease injury in the early post transplant period. AIM 2: To test the hypothesis that ischemic preconditioning of deceased donor livers would decrease systemic inflammatory response in liver recipients in the early post transplant period. AIM 3: To examine whether ischemic preconditioning of deceased donor livers decreases early post transplant pulmonary edema and acute rejection and shortens hospital stay.


Condition Intervention Phase
Liver Cirrhosis
Liver Transplantation
Procedure: Ischemic Preconditioning
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Ischemic Preconditioning of Liver in Cadaver Donors

Resource links provided by NLM:


Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • INR/PT and serum AST, ALT and TB levels

Secondary Outcome Measures:
  • Plasma levels of cytokines
  • Interstitial and alveolar edema in chest radiographs
  • Length of Hospital stay

Estimated Enrollment: 100
Study Start Date: October 2003
Study Completion Date: March 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Deceased donor livers allocated to adult (> 18 years of age) recipients at the research site.

Exclusion Criteria:

  1. Deceased donor livers allocated to recipients at centers other than the research site.
  2. Deceased donor livers allocated to recipients < 18 years of age at the research site.
  3. Non-heart beating donors
  4. Deceased liver and small intestine donors
  5. Live liver donors.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00245830

Locations
United States, New Jersey
University Hospital
Newark, New Jersey, United States, 07101
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
Investigators
Principal Investigator: Baburao Koneru, M.D. UMDNJ-New Jersey Medical School
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00245830     History of Changes
Other Study ID Numbers: 0120010348
Study First Received: October 26, 2005
Last Updated: April 27, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Rutgers, The State University of New Jersey:
Ischemia/reperfusion of the liver
Ischemic Preconditioning
Cadaver organ donor

Additional relevant MeSH terms:
Cadaver
Liver Cirrhosis
Death
Digestive System Diseases
Liver Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on October 22, 2014